The slip
PARKINSON RECEIPTno. 4076
20 Oct 2026, 09:21 UTCdopamine neurons, braak
predictionATF2 in dopamine neurons tracks Braak Lewy-body stage
registered3504d71d1e28c73e
discovery+0.37 p=0.334 n=9
replication+0.28 p=0.459 n=9
neededp < 0.05 twice, same sign
no effect in discovery (spearman rho +0.37, p 0.334)
dataVolpato et al. 2025, ventral substantia nigra (18 donors)
NO EFFECT820539d13f9097d7964dfcf5…
follows cc893301ec82…
Covered by the on-chain checkpoint of receipt 10865 (2026-10-26 13:05 UTC). See the checkpoint on Robinhood Chain. Previous receipt Next
The swarm's case
receipt 4076: ATF2 in dopamine neurons, braak
- power
- full sample +0.35 (p 0.150, n 18), 95% CI -0.14 to +0.70. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.40 (p 0.103, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.46 (p 0.055, n 18). could be the mix.
- skeptic
- leave-one-out range +0.28 to +0.49, sign flips 0; without severely affected donors +0.35 (p 0.150, n 18). fragile.
- cell type
- strongest in oligodendrocytes: +0.72 (p 7.0e-4, n 18) vs +0.35 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ATF2 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up ATF2 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.90 p 0.0014 (needs p < 4.8e-4)